{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:03:57Z","timestamp":1790694237693,"version":"4.1.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T00:00:00Z","timestamp":1581984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"DOI":"10.3389\/fendo.2020.00061","type":"journal-article","created":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T00:48:01Z","timestamp":1581986881000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":28,"title":["Temozolomide Is a Potential Therapeutic Tool for Patients With Metastatic Pheochromocytoma\/Paraganglioma\u2014Case Report and Review of the Literature"],"prefix":"10.3389","volume":"11","author":[{"given":"Anli","family":"Tong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunying","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosen","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,2,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1210\/jc.2013-1907","article-title":"One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma","volume":"98","author":"Hescot","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"key":"B2","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/cen.12341","article-title":"(131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis","volume":"80","author":"van Hulsteijn","year":"2014","journal-title":"Clin Endocrinol"},{"key":"B3","first-page":"1599","article-title":"Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma","volume":"47","author":"van Essen","year":"2006","journal-title":"J Nucl Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.1210\/jc.2012-2356","article-title":"Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas","volume":"97","author":"Ayala-Ramirez","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"key":"B5","article-title":"NCCN clinical practice guidelines in oncology: neuroendocrine and adrenal tumors","author":"Shah","year":"2019","journal-title":"J Natl Compr Canc Netw."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s10571-018-0579-4","article-title":"Continued tumor reduction of metastatic pheochromocytoma\/paraganglioma harboring succinate dehydrogenase subunit B mutations with cyclical chemotherapy","volume":"38","author":"Jawed","year":"2018","journal-title":"Cell Mol Neurobiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/cen.12542","article-title":"Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis","volume":"81","author":"Niemeijer","year":"2014","journal-title":"Clin Endocrinol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1200\/JCO.2005.03.6046","article-title":"Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors","volume":"24","author":"Kulke","year":"2006","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1158\/1078-0432.CCR-06-2053","article-title":"Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors","volume":"13","author":"Ekeblad","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1055\/s-0029-1224135","article-title":"Clinical utility of temozolomide in the treatment of malignant paraganglioma: a preliminary report","volume":"41","author":"Bravo","year":"2009","journal-title":"Horm Metab Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1530\/EJE-11-1098","article-title":"A SDHB malignant paraganglioma with dramatic response to temozolomide-capecitabine","volume":"166","author":"Nozi\u00e8res","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1002\/ijc.28913","article-title":"SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma","volume":"135","author":"Hadoux","year":"2014","journal-title":"Int J Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.12688\/f1000research.13185.1","article-title":"Case report: propranolol increases the therapeutic response to temozolomide in a patient with metastatic paraganglioma","volume":"6","author":"D\u00edaz-Castellanos","year":"2017","journal-title":"F1000Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1179554918763367","article-title":"Successful second-line metronomic temozolomide in metastatic paraganglioma: case reports and review of the literature","volume":"12","author":"Tena","year":"2018","journal-title":"Clin Med Insights Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1097\/CAD.0000000000000570","article-title":"Temozolomide treatment of a malignant pheochromocytoma and an unresectable MAX-related paraganglioma","volume":"29","author":"Ferrara","year":"2018","journal-title":"Anticancer Drugs"},{"key":"B16","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1093\/jnen\/nlz032","article-title":"Posttreatment effect of MGMT methylation level on glioblastoma survival","volume":"78","author":"Dahlrot","year":"2019","journal-title":"J Neuropathol Exp Neurol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1111\/joim.12507","article-title":"Precision medicine in pheochromocytoma and paraganglioma: current and future concepts","volume":"280","author":"Bj\u00f6rklund","year":"2016","journal-title":"J Intern Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1210\/er.2017-00062","article-title":"New Perspectives on pheochromocytoma and paraganglioma: toward a molecular classification","volume":"38","author":"Crona","year":"2017","journal-title":"Endocr Rev."},{"key":"B19","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1056\/NEJMra1806651","article-title":"Pheochromocytoma and paraganglioma","volume":"381","author":"Neumann","year":"2019","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1159\/000500862","article-title":"Temozolomide alone or combined to capecitabine for the treatment of advanced pancreatic NET","volume":"110","author":"Mestier","year":"2020","journal-title":"Neuroendocrinology."},{"key":"B21","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s12020-018-1751-9","article-title":"Tumoral MGMT content predicts survival in patients with aggressive pituitary tumors and pituitary carcinomas given treatment with temozolomide","volume":"62","author":"Bengtsson","year":"2018","journal-title":"Endocrine"},{"key":"B22","doi-asserted-by":"publisher","first-page":"102","DOI":"10.2174\/1874467211205010102","article-title":"Temozolomide: mechanisms of action, repair and resistance","volume":"5","author":"Zhang","year":"2012","journal-title":"Curr Mol Pharmacol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1158\/0008-5472.CAN-16-2983","article-title":"Temozolomide in the era of precision medicine","volume":"77","author":"Thomas","year":"2017","journal-title":"Cancer Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.1158\/1078-0432.CCR-14-2804","article-title":"DNA methylation profiling in pheochromocytoma and paraganglioma reveals diagnostic and prognostic markers","volume":"21","author":"de Cubas","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","article-title":"Comprehensive molecular characterization of pheochromocytoma and paraganglioma","volume":"31","author":"Fishbein","year":"2017","journal-title":"Cancer Cell"},{"key":"B26","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S1470-2045(17)30194-8","article-title":"European association for neuro-oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1159\/000430816","article-title":"Temozolomide in advanced neuroendocrine neoplasms: pharmacological and clinical aspects","volume":"101","author":"Koumarianou","year":"2015","journal-title":"Neuroendocrinology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e12784","DOI":"10.1097\/MD.0000000000012784","article-title":"Safety and efficacy of combining capecitabine and temozolomide (CAPTEM) to treat advanced neuroendocrine neoplasms: a meta-analysis","volume":"97","author":"Lu","year":"2018","journal-title":"Medicine."}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2020.00061\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T00:48:04Z","timestamp":1581986884000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2020.00061\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,18]]},"references-count":29,"alternative-id":["10.3389\/fendo.2020.00061"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2020.00061","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,18]]},"article-number":"61"}}